160 related articles for article (PubMed ID: 32040880)
1. Early detection and follow-up of colorectal neoplasia based on faecal volatile organic compounds.
Bosch S; Bot R; Wicaksono A; Savelkoul E; van der Hulst R; Kuijvenhoven J; Stokkers P; Daulton E; Covington JA; de Meij TGJ; de Boer NKH
Colorectal Dis; 2020 Sep; 22(9):1119-1129. PubMed ID: 32040880
[TBL] [Abstract][Full Text] [Related]
2. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study.
de Meij TG; Larbi IB; van der Schee MP; Lentferink YE; Paff T; Terhaar Sive Droste JS; Mulder CJ; van Bodegraven AA; de Boer NK
Int J Cancer; 2014 Mar; 134(5):1132-8. PubMed ID: 23959518
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer and adenoma screening using urinary volatile organic compound (VOC) detection: early results from a single-centre bowel screening population (UK BCSP).
Mozdiak E; Wicaksono AN; Covington JA; Arasaradnam RP
Tech Coloproctol; 2019 Apr; 23(4):343-351. PubMed ID: 30989415
[TBL] [Abstract][Full Text] [Related]
4. Urinary volatile organic compounds for colorectal cancer screening: A systematic review and meta-analysis.
van Liere ELSA; van Dijk LJ; Bosch S; Vermeulen L; Heymans MW; Burchell GL; de Meij TGJ; Ramsoekh D; de Boer NKH
Eur J Cancer; 2023 Jun; 186():69-82. PubMed ID: 37030079
[TBL] [Abstract][Full Text] [Related]
5. Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer.
van Keulen KE; Jansen ME; Schrauwen RWM; Kolkman JJ; Siersema PD
Aliment Pharmacol Ther; 2020 Feb; 51(3):334-346. PubMed ID: 31858615
[TBL] [Abstract][Full Text] [Related]
6. Detecting Colorectal Adenomas and Cancer Using Volatile Organic Compounds in Exhaled Breath: A Proof-of-Principle Study to Improve Screening.
Cheng HR; van Vorstenbosch RWR; Pachen DM; Meulen LWT; Straathof JWA; Dallinga JW; Jonkers DMAE; Masclee AAM; Schooten FV; Mujagic Z; Smolinska A
Clin Transl Gastroenterol; 2022 Nov; 13(11):e00518. PubMed ID: 35981245
[TBL] [Abstract][Full Text] [Related]
7. Fecal volatile organic compounds for early detection of colorectal cancer: where are we now?
Bosch S; Berkhout DJ; Ben Larbi I; de Meij TG; de Boer NK
J Cancer Res Clin Oncol; 2019 Jan; 145(1):223-234. PubMed ID: 30554400
[TBL] [Abstract][Full Text] [Related]
8. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
[TBL] [Abstract][Full Text] [Related]
9. Long-term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps.
He X; Hang D; Wu K; Nayor J; Drew DA; Giovannucci EL; Ogino S; Chan AT; Song M
Gastroenterology; 2020 Mar; 158(4):852-861.e4. PubMed ID: 31302144
[TBL] [Abstract][Full Text] [Related]
10. Effects of Curative Colorectal Cancer Surgery on Exhaled Volatile Organic Compounds and Potential Implications in Clinical Follow-up.
Altomare DF; Di Lena M; Porcelli F; Travaglio E; Longobardi F; Tutino M; Depalma N; Tedesco G; Sardaro A; Memeo R; de Gennaro G
Ann Surg; 2015 Nov; 262(5):862-6; discussion 866-7. PubMed ID: 26583677
[TBL] [Abstract][Full Text] [Related]
11. Contribution of Surveillance Colonoscopy to Colorectal Cancer Prevention.
Pinsky PF; Schoen RE
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2937-2944.e1. PubMed ID: 32017987
[TBL] [Abstract][Full Text] [Related]
12. Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer.
Bond A; Greenwood R; Lewis S; Corfe B; Sarkar S; O'Toole P; Rooney P; Burkitt M; Hold G; Probert C
Aliment Pharmacol Ther; 2019 Apr; 49(8):1005-1012. PubMed ID: 30828825
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers.
Widlak MM; Neal M; Daulton E; Thomas CL; Tomkins C; Singh B; Harmston C; Wicaksono A; Evans C; Smith S; Savage RS; Covington JA; Arasaradnam RP
Colorectal Dis; 2018 Dec; 20(12):O335-O342. PubMed ID: 30248228
[TBL] [Abstract][Full Text] [Related]
14. Urinary volatile organic compounds and faecal microbiome profiles in colorectal cancer.
McFarlane M; Millard A; Hall H; Savage R; Constantinidou C; Arasaradnam R; Nwokolo C
Colorectal Dis; 2019 Nov; 21(11):1259-1269. PubMed ID: 31282600
[TBL] [Abstract][Full Text] [Related]
15. Low detection rate of advanced neoplasia within 5 years after polypectomy of small serrated adenoma.
Jin D; Cao H; Shah BK; Chen D; Zhang Y; Liu T; Dong W; Wang S; Qi Y; Wang B
Postgrad Med J; 2019 Apr; 95(1122):187-192. PubMed ID: 30926717
[TBL] [Abstract][Full Text] [Related]
16. Colorectal cancer and advanced adenoma incidence during post-polypectomy surveillance: a national cohort study in the English Bowel Cancer Screening Programme.
Bonnington SN; Hungin APS; Nickerson C; Wright S; Sharp L; Rutter MD
Endoscopy; 2023 Aug; 55(8):740-753. PubMed ID: 37185968
[TBL] [Abstract][Full Text] [Related]
17. Breath testing as potential colorectal cancer screening tool.
Amal H; Leja M; Funka K; Lasina I; Skapars R; Sivins A; Ancans G; Kikuste I; Vanags A; Tolmanis I; Kirsners A; Kupcinskas L; Haick H
Int J Cancer; 2016 Jan; 138(1):229-36. PubMed ID: 26212114
[TBL] [Abstract][Full Text] [Related]
18. Colonoscopy surveillance for high risk polyps does not always prevent colorectal cancer.
Mouchli MA; Ouk L; Scheitel MR; Chaudhry AP; Felmlee-Devine D; Grill DE; Rashtak S; Wang P; Wang J; Chaudhry R; Smyrk TC; Oberg AL; Druliner BR; Boardman LA
World J Gastroenterol; 2018 Feb; 24(8):905-916. PubMed ID: 29491684
[TBL] [Abstract][Full Text] [Related]
19. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
[No Abstract] [Full Text] [Related]
20. Intermediate-risk patients with three to four small adenomas should be considered low risk for colorectal cancer screening.
Pérez-Cuadrado-Robles E; Torrella-Cortés E; Bebia-Conesa P; Quesada-Vázquez N; Rodrigo-Agudo JL; Chacón-Martínez S; López-Martín A; Esteban-Delgado P; Pérez-Cuadrado-Martínez E; Pérez-Riquelme F
Dig Endosc; 2016 May; 28(4):450-455. PubMed ID: 26538148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
